Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
Terminated · Phase 2 · NCT04853368
Conditions: Cystic Fibrosis (CF)
At a glance
- Research payments reported, 2025
- $1,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-576 (drug), Galicaftor (drug), Placebo (drug), Navocaftor (drug), ABBV-119 (drug)
- Dates
- Started 2021-09-20; completion 2023-06-05
- Results posted
- Yes
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The main objective of this study is to assess how safe and effective is the combination therapy of galicaftor/navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 in adult participants with CF who are homozygous or heterozygous for the F508del mutation in each arm. Galicaftor/Navocaftor/ABBV-119 combination therapy and Galicaftor/Navocaftor/ABBV-576 is being developed as an investigational drug for the treatment of CF. Study doctors place participants in 1 of the 4 groups, called…
From ClinicalTrials.gov, last updated 2024-07-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- New York Medical College $1,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.